FDA
-
-
-
-
-
-
-
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
-
-
-
-
-
-
-
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
-
-
-
-
-
-
-
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
-
-
-
-
-
-
-
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
-
-
-
-
-
-
-
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
-
-
-
-
-
-
-
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
-
-
-
-
-
-
-
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
-
323,571 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

